OR WAIT null SECS
January 14, 2025
Video
Flemming describes increasing rates of AH among adolescents and young adults, with females facing the greatest increases and worse outcomes than males.
Article
In patients with MASLD and T2D, GLP-1 RA use was linked to a 16% relative risk reduction in major adverse liver outcomes compared with SGLT2i use.
January 13, 2025
Pediatric liver transplant centers with greater within-center variability in induction type had higher rates of 1-year rejection.
January 09, 2025
Study findings suggest patients with MASLD face a 2.59-fold increased risk of heart failure, especially HFpEF, relative to those without MASLD.
Study findings highlight increasing rates of AH among adolescents and younger adults, with women facing worse long-term liver-related outcomes.
January 08, 2025
From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in ALD and MASLD.
The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting
January 07, 2025
Findings suggest the potential value of anti-gliadin and anti-F-actin IgA for risk stratification in patients with primary sclerosing cholangitis.
January 02, 2025
The December month in review spotlights hepatic FDA news as well as the latest research in viral hepatitis and MASH.
December 31, 2024
To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.
